Immunotherapy efficacy and patient’s sex in advanced or metastatic non-small cell lung cancer: a systematic review and network meta-analysis
Year: 2026
Type: article
Study designs: Systematic Review, Meta-Analysis
Abstract: Immune checkpoint inhibitors (ICIs), particularly anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1), alone or combined with chemotherapy (CT), are the gold standard for first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). Guidelines strongly recommend anti-PD-1/PD-L1 (anti-PD-(L)1) monotherapy when PD-L1 tumor proportion score (TPS) is ≥ 50%. Emerging evidence suggests that also sex may influence ICI efficacy. The objective of this study was to estimate sex-based differences in the relative efficacy between anti-PD-(L)1 + CT and anti-PD-(L)1 monotherapy. This study is a systematic review and network meta-analysis of phase II/III randomized controlled trials evaluating ICI-based regimens containing anti-PD-(L)1 or anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), alone or combined with CT, versus any control arm in advanced NSCLC, focusing on sex-specific treatment effects. Fifty trials including 29,002 patients were analyzed. For each treatment comparison, differences between males and females were assessed by calculating the ratio of hazard ratios (HRs) for males (HR-M) versus females (HR-F), separately for overall survival (OS) and progression-free survival (PFS). For OS, anti-PD-(L)1 + CT significantly improved outcomes in females compared to anti-PD-(L)1 monotherapy [HR-F (95% CI) = 0.84 (0.73–0.96)], while no significant difference was seen in males [HR-M = 0.99 (0.90–1.10)]. The pooled ratio of hazard ratios favored females [Ratio-HR = 1.20 (1.01–1.42), p = 0.04]. Similar trends were observed for PFS. Anti-CTLA-4, whether combined with CT, anti-PD-(L)1, or both, did not yield superior outcomes compared to anti-PD-(L)1 monotherapy. These findings suggest that sex may modulate the efficacy of ICI in advanced NSCLC, possibly due to underlying sex differences in the hormone-mediated immune response. However, our results should be interpreted with caution and require confirmation, since the evidence was largely indirect and some estimates did not meet the threshold for clinical relevance. PROSPERO CRD42024597267
Source: Systematic Reviews
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,090
Award: G5217129850
OpenAlex ID: W7227856162
